---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000053"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:32:16.653524+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised

## Summary
- Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.
- Qelbree net sales $77.6M (+31% YoY); GOCOVRI net sales $36.7M (+16% YoY); 225k IQVIA prescriptions.
- Adjusted operating earnings (non-GAAP) $40.9M; operating income $12.1M; raising FY 2025 guidance.
- Closed Sage Therapeutics acquisition on July 31, adding ZURZUVAE; ONAPGO launch: 750+ enrollment forms.

## SEC filing metadata
- accession: 0001356576-25-000053
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/0001356576-25-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000053/supn-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000053
- JSON: https://secwatch.observer/filing/0001356576-25-000053.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.